ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Warszawa, Mazowieckie, POL:

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess...

Enrolling
Mantle Cell Lymphoma (MCL)
Drug: Venetoclax
Drug: Rituximab

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 47 other locations

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: CPI-0209

Phase 1, Phase 2

Constellation Pharmaceuticals

Warsaw, Poland and 49 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

Warszawa, Poland and 73 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Warszawa, Poland and 215 other locations

The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 w...

Active, not recruiting
Lymphoma
Drug: Brentuximab vedotin

Phase 4

Takeda
Takeda

Warszawa, Poland and 39 other locations

purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma...

Active, not recruiting
Lymphoma
Drug: Parsaclisib

Phase 2

Incyte
Incyte

Warszawa, Poland and 82 other locations

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Begins enrollment in 1 month
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2

Celgene
Celgene

Warszawa, Mazowieckie, Poland and 64 other locations

in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton...

Active, not recruiting
Lymphoma
Drug: Parsaclisib

Phase 2

Incyte
Incyte

Warsaw, Poland and 85 other locations

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoc...

Active, not recruiting
Mantle-Cell Lymphoma
Drug: Ibrutinib
Drug: Venetoclax

Phase 3

Pharmacyclics
Pharmacyclics

Warszawa, Poland and 119 other locations

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemoth...

Enrolling
Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Drug: Gemcitabine
Drug: Rituximab

Phase 3

ADC Therapeutics

Warszawa, Poland and 140 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems